Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Nymox Pharmaceutical (NASDAQ:NYMX) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Nymox and see what CAPS investors are saying about the stock right now.

Nymox facts

Headquarters (founded)

St Laurent, Canada (1989)

Market Cap

$279.1 million



Trailing-12-Month Revenue

$3.1 million


CEO Dr. Paul Averback (since 1995)
CFO Roy Wolvin (since 1995)

Return on Assets (average, past three years)



$2.2 million / $0


Abbott Labs (NYSE:ABT)
Laboratory Corp.

Sources: S&P Capital IQ; Motley Fool CAPS.

On CAPS, 38% of the 82 members who have rated Nymox believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, cautioned our community about the stock's recent surge:

When Nymox stock trailed down from steady state at [$8 per share] to below [$6 per share] this summer, I figured the smart money was leaving ahead of negative results from the phase III trials of NX-1207 for BPH. Now I'm surprised to see the share price rocketing back up close to the year high without any visible positive catalyst. This definitely doesn't have the characteristics of a run-up, so is it insider trading ahead of a positive data announcement? I can't say that's impossible, but I'm going to call it stirrapulation and place my bet on negative data from this murky trial from a very murky biopharma.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.